Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Dec;51(10):602-9. doi: 10.1016/j.aprim.2017.10.012
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Barbe F, Castan MT, Seminario MA, Pujol J, Alseda M. Comment: Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers. Aten Primaria. 2019 Nov;51(9):589-90.
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Cruz-Esteve I, Marsal-Mora JR, Galindo-Ortego G, Galvan-Santiago L, Serrano-Godoy M, Ribes-Murillo E, Real-Gatius J, en representacion del grupo de investigacion GRETAP. Potentially inappropriate prescribing in older Spanish population according to STOPP/START criteria (STARTREC Study). Aten Primaria. 2017 Mar;49(3):166-76. doi: 10.1016/j.aprim.2016.02.013
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe-Illa F. Risk factors for mortality in patients with chronic obstructive pulmonary disease. Aten Primaria. 2015 Oct;47(8):498-504. doi: 10.1016/j.aprim.2014.11.004
Puente D, Zabaleta-Del-Olmo E, Pueyo MJ, Salto E, Marsal JR, Bolibar B. Cigarette smoking prevalence and associated factors in secondary school children in Catalunya. Aten Primaria. 2013 Jun;45(6):315-23. doi: 10.1016/j.aprim.2012.12.007
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.